Seeking Alpha

More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well...

More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well revenue. Total sales declined 24% Y/Y, mainly due to the recording of a $2.6M milestone payment from Yakult for the initiation of Phase 1 trials for perifosine in Japan during Q411. Operational expenses declined due to lower employee compensation and benefit costs and a reduced headcount at the drug developer.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (2)
  • ah9796
    , contributor
    Comments (10) | Send Message
     
    Is there a light at the end of the tunnel????
    21 Mar 2013, 10:42 PM Reply Like
  • mofisher22
    , contributor
    Comments (100) | Send Message
     
    If there is, it must be a mighty long tunnel.
    22 Mar 2013, 08:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs